WORCESTER, Mass.--(BUSINESS WIRE)--July 18, 2006--Biovest International, Inc. (OCTBB: BVTI) has received regulatory approval from the Russian Ministry of Health and Social Development of the Russian Federation to recruit patients for its ongoing Phase 3 clinical trial of BiovaxID(TM) for the treatment of indolent follicular non-Hodgkin’s lymphoma (NHL).
